ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
5.25
2.05
( 64.06% )
Updated: 03:03:35

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
5.25
Bid
5.00
Offer
5.50
Volume
20,690,521
3.25 Day's Range 8.625
3.20 52 Week Range 10.125
Market Cap
Previous Close
3.20
Open
3.25
Last Trade Time
03:05:29
Financial Volume
1,424,004p
VWAP
6.8824
Average Volume (3m)
45,901
Shares Outstanding
176,960,000
Dividend Yield
-
PE Ratio
-1.42
Earnings Per Share (EPS)
-0.04
Revenue
2.16M
Net Profit
-7.02M

About Genincode Plc

Sector
Coml Physical, Biologcl Resh
Industry
Coml Physical, Biologcl Resh
Headquarters
Manchester, Gbr
Founded
-
Genincode Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENI. The last closing price for Genincode was 3.20p. Over the last year, Genincode shares have traded in a share price range of 3.20p to 10.125p.

Genincode currently has 176,960,000 shares in issue. The market capitalisation of Genincode is £5.66 million. Genincode has a price to earnings ratio (PE ratio) of -1.42.

GENI Latest News

GENinCode shares rally on test inclusion in clinical lab fee schedule

GENinCode PLC on Thursday saw its share price more than double as it reported key developments relating to its Cardio ...

GENinCode PLC CARDIO inCode Lab Fee Update & Catalonia Launch

GENinCode PLC 23 January 2025   23 January 2025     GENinCode Plc ("GENinCode" or the "Company")   CARDIO inCode® inclusion in the US CMS 2025 Clinical Lab Fee Schedule and launch in the...

GENinCode PLC Partnership with Genesupport SA for the ROCA® Test

GENinCode PLC 10 December 2024   GENinCode Plc ("GENinCode" or the "Company")   GENinCode partners with Genesupport SA for the ROCA® Test in Switzerland Ovarian cancer surveillance using the...

GENinCode PLC CARDIO inCode® publication & Trading Update

GENinCode PLC 05 December 2024   5 December 2024     GENinCode Plc ("GENinCode" or the "Company")   CARDIO inCode® publication in International Journal of Cardiology Cardiovascular Risk and...

EARNINGS: Origin Enterprises profit falls; GENinCode loss narrows

The following is a round-up of earnings for London-listed companies, issued on Wednesday and Tuesday and not separate ...

GENinCode PLC Half-year Report

GENinCode PLC 25 September 2024     25 September 2024 GENinCode Plc ("GENinCode", the "Company" or the "Group")   Interim report First US commercial sales for LIPID inCode® and CARDIO inCode®...

GENinCode partners with medical centres for cardiovascular screening

GENinCode PLC on Friday announced its collaboration with The Family Heart Foundation, the University of Texas Southwe ...

GENinCode PLC Collaboration with The Family Heart Foundation

GENinCode PLC 20 September 2024   GENinCode Plc ("GENinCode" or the "Company")   DISCOVER FH collaboration with Family Heart Foundation®, UT Southwestern, and Partners LIPID inCode®, tests...

GENinCode PLC Notice of Results

GENinCode PLC 09 September 2024   9 September 2024 GENinCode Plc ("GENinCode" or the "Company")   Notice of results Analyst and investor briefing   Oxford, UK. GENinCode Plc (AIM: GENI), the...

GENinCode PLC CARDIO inCode-Score presentation

GENinCode PLC 28 August 2024   GENinCode Plc ("GENinCode" or the "Company")   CARDIO inCode-Score® presentation on polygenic risk of Coronary Heart Disease at 2024 European Society of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.9559.09090909093.38.6253.2693243.22311516DE
41.4538.15789473683.88.6253.2507143.36166291DE
121.126.50602409644.158.6253.2459013.77239957DE
26-0.45-7.894736842115.78.6253.2751865.34483491DE
520.357.142857142864.910.1253.21703476.29367954DE
156-27.75-84.090909090933333.212362210.48258723DE
260-43.25-89.17525773248.548.53.212018313.82210154DE

GENI - Frequently Asked Questions (FAQ)

What is the current Genincode share price?
The current share price of Genincode is 5.25p
How many Genincode shares are in issue?
Genincode has 176,960,000 shares in issue
What is the market cap of Genincode?
The market capitalisation of Genincode is GBP 5.66M
What is the 1 year trading range for Genincode share price?
Genincode has traded in the range of 3.20p to 10.125p during the past year
What is the PE ratio of Genincode?
The price to earnings ratio of Genincode is -1.42
What is the cash to sales ratio of Genincode?
The cash to sales ratio of Genincode is 4.61
What is the reporting currency for Genincode?
Genincode reports financial results in GBP
What is the latest annual turnover for Genincode?
The latest annual turnover of Genincode is GBP 2.16M
What is the latest annual profit for Genincode?
The latest annual profit of Genincode is GBP -7.02M
What is the registered address of Genincode?
The registered address for Genincode is ONE, ST. PETERS SQUARE, MANCHESTER, M2 3DE
What is the Genincode website address?
The website address for Genincode is www.genincode.com
Which industry sector does Genincode operate in?
Genincode operates in the COML PHYSICAL, BIOLOGCL RESH sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GENIGenincode Plc
5.25p
(64.06%)
20.47M
EMEEmpyrean Energy Plc
0.125p
(56.25%)
1.05B
WJGWatkin Jones Plc
24.75p
(24.75%)
12.11M
CLAICel Ai Plc
0.38p
(22.58%)
24.4M
MFAIMindflair Plc
1.25p
(19.05%)
84.68M
PPSProton Motor Power Systems Plc
0.175p
(-41.67%)
1.53M
ENWEnwell Energy Plc
17.50p
(-25.53%)
238.06k
QBTQuantum Blockchain Technologies Plc
1.185p
(-24.76%)
132.93M
MILAMila Resources Plc
0.175p
(-22.22%)
17.54M
REVBRevolution Beauty Group Plc
11.50p
(-18.56%)
7.29M
SYMESupply@me Capital Plc
0.0027p
(-8.47%)
1.31B
EMEEmpyrean Energy Plc
0.125p
(56.25%)
1.05B
NTVONativo Resources Plc
0.0021p
(5.00%)
862.02M
TRPTower Resources Plc
0.0275p
(-6.78%)
351.79M
MSMNMosman Oil And Gas Limited
0.025p
(-7.41%)
244.69M

Discussion

View Full Feed
stockprofitter stockprofitter 5 minutes ago
Yadda yadda yadda. It is a $33 IPO assuming warrants are exercised and 5X if they are not.
FNMA
sharky sharky 5 minutes ago
They have been keeping this one down too long here IMO. Revenues looking good for a trip. Accumulation picking up also.
ASII
JStewin JStewin 5 minutes ago
Is this rally driven by Trumps AI energy support? What is the target here?
OKLO
WilliamMunny WilliamMunny 5 minutes ago
BTW, a number of people here have indicated that Missling said the company was awaiting the finalization of the draft guidance before filing at the FDA. I actually don't recall him saying that, although I may not have been paying close enough attention at the time. Can anyone help me by pointing o
JPM
JTORENCE JTORENCE 5 minutes ago
Just telling it like it is SNOWFLAKE.
NWBO
crowin crowin 5 minutes ago
Yes give the SEC RDARS number!
RDAR
surfer44 surfer44 5 minutes ago
Paul & Linda McCartney — Uncle Albert/Admiral Halsey (Official)

https://youtu.be/zFxRKvxfCAw
GARYM1 GARYM1 6 minutes ago
I think the updates of the past are done as you can only state how great your product is and how big the market is so long and we are at that point in time.
They missed more then the first round of roll out.
SEV
La Flaca La Flaca 6 minutes ago
The point of the article is that trialists have relied on guidance from FDA, even "draft" guidance to design their trials. Anavex can do the same. I'm certain I can find examples of trialists relying on "draft guidances" (for trial designs) even those in which FDA sought comments. I think the conten
AVXL
doc2016 doc2016 6 minutes ago
kona, next question is when did samsung consider trying these quantum phenomenon apps/ai? did lg or interwoven have such?
IONQ
F14SVF24 F14SVF24 6 minutes ago
Another great straight up post NoMoDo. I thought about the Romans and their last stand. Like xkay. "Romans" hence the X symbol. But you got it. But HMBL is in a good position for the long haul.
HMBL
Saving Grace Saving Grace 6 minutes ago
Institutions loading heavily! Silver screen institutional buying large.
HYMC
vinnie1965 vinnie1965 6 minutes ago
SMH
TGLO
NoMoDo NoMoDo 6 minutes ago
This has been my beef. Us older people need clear instructions.However, it did not include the clear on-ramp and off-ramp for fiat currency.Good to hear that you liked the functionality.
HMBL
shamalamadingdong shamalamadingdong 7 minutes ago
Senator Cynthia Lummis is chair of the Senate Banking Subcommittee on Digital Assets, and CZ Reacts to Senator Cynthia Lummis' Appointment, Hints at U.S. Strategic Bitcoin Reserve.
https://www.binance.com/en/square/post/01-23-2025-cz-reacts-to-senator-cynthia-lummis-appointment-hints-at-u-s-s
BTCUSD
22rover 22rover 7 minutes ago
Let’s consider a scenario where there are 1,000 shareholders (that's a decent ballpark # for sc). At any given moment, it’s reasonable to expect around 1% of holders will decide to sell. This isn’t far-fetched at all. A portion of that 1% may go through a full-service broker—perhaps they use Schwab
SDCH
TrendTrade2016 TrendTrade2016 7 minutes ago
UPXI BLOWING UP OFF BOTTOM
UPXI
sammdogg1 sammdogg1 7 minutes ago
Hang on to your shares is great advice here. There's been downward pressure, and when there is we have always seen accompanying opinion as to why this company is finished. This time it's "slowing growth" or obstacles to growth. Stock prices aside, the one thing this company has always done is grow a
IDCC
Myth Myth 7 minutes ago
May 2015

Revised Form 10 to be Promptly Re-Filed with the S.E.C.
Dear HHSE Friends - As previously reported, HHSE was informed on April 28 that our prior auditor (Terry L. Johnson) had lost his authority to sign-off on Public Company audits. Accordingly, and without delay, HHS
HHSE
janetcanada janetcanada 7 minutes ago
👀***RDAR - A Good link....
***Email us at: Help@sec.gov
RDAR
branster branster 8 minutes ago
Investor082, of course after a big spike you will get a pullback, that is normal. But, you take a big risk of selling on the spike assuming big pullbacks are coming.
Approval is just the beginning not the end, approval opens the possibility door for all sorts of catalyst on the horizon. App
NWBO
Pro_v12001 Pro_v12001 8 minutes ago
Jabil took over Intel's Silicon photonics division. Lets partner with Jabil!

https://www.jabil.com/news/jabil-invests-future-ai-intel-silicon-photonics-transceiver.html
LWLG
eb0783 eb0783 8 minutes ago
Atossa Therapeutics Issues Letter to Shareholders Highlighting 2024 Accomplishments and Outlook for 2025.

https://investors.atossatherapeutics.com/news-releases/news-release-details/atossa-therapeutics-issues-letter-shareholders-highlighting-2024
ATOS
Getn otta det Getn otta det 8 minutes ago
You will oftentimes see gaps right around the earnings call. If the earnings beat expectations by a lot, then that most likely results in a runaway gap that may not ever get filled. That's not what's happened with us here. But imo it will just cycle lower to fill and then bounce higher, to a new
COOP

Your Recent History

Delayed Upgrade Clock